Sucampo Pharmaceuticals CEO Ryuji Ueno Sells 38,462 Shares (SCMP)
Sucampo Pharmaceuticals (NASDAQ:SCMP) CEO Ryuji Ueno sold 38,462 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $5.69, for a total transaction of $218,848.78. Following the transaction, the chief executive officer now directly owns 148,530 shares of the company’s stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
SCMP has been the subject of a number of recent research reports. Analysts at Cantor Fitzgerald cut their price target on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from $9.00 to $7.00 in a research note to investors on Tuesday, September 3rd. They now have a “buy” rating on the stock. Separately, analysts at Maxim Group downgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, September 3rd. They now have a $7.00 price target on the stock, down previously from $9.00. Finally, analysts at Zacks upgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from an “underperform” rating to a “neutral” rating in a research note to investors on Tuesday, August 20th. They now have a $6.20 price target on the stock.
Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Sucampo Pharmaceuticals has a consensus rating of “Hold” and an average price target of $8.44.
Sucampo Pharmaceuticals (NASDAQ:SCMP) traded down 1.05% during mid-day trading on Wednesday, hitting $5.68. The stock had a trading volume of 129,025 shares. Sucampo Pharmaceuticals has a 1-year low of $4.41 and a 1-year high of $10.48. The stock has a 50-day moving average of $6.03 and a 200-day moving average of $6.93. The company has a market cap of $237.8 million and a P/E ratio of 22.60.
Sucampo Pharmaceuticals, Inc is a pharmaceutical Company. The Company is focused on the discovery, development and commercialization of drugs based on prostones.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.